Skip to main content
OpenTrials
Completed

NCT Number: NCT07327320

Norepinephrine vs. Phenylephrine for Hypotension in Low-Dose Spinal Anesthesia for Cesarean Delivery

This clinical trial was conducted to compare the effectiveness and safety of two medications, norepinephrine and phenylephrine, in preventing hypotension during low-dose spinal anesthesia for cesarean delivery (CD). Although low-dose spinal anesthesia combined with opioids is widely used to mitigate hypotension, the incidence remains unacceptably high. Thus, vasopressors remain essential in maintaining maternal blood pressure during these procedures.

In this study, 100 women were initially assessed, with 2 excluded. The remaining 98 were randomly assigned to receive a continuous infusion of either norepinephrine or phenylephrine. During the follow-up process, 2 patients from each group were lost, resulting in 47 participants per group for final analysis.

The results showed that norepinephrine was significantly more effective, with a lower incidence of hypotension (14.9% vs. 42.6%). It also provided more stable heart rates with fewer episodes of bradycardia and less need for rescue medications. Both treatments were safe for the babies with comparable Apgar scores.

This study suggests that Norepinephrine infusion at 0.05 mcg/kg/min is more effective than phenylephrine at 0.25 mcg/kg/min in preventing hypotension during low-dose SA in CD, providing better hemodynamic stability and fewer episodes of bradycardia

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Tam Anh TP. Ho Chi Minh General Hospital

Ho Chi Minh City, Ho Chi Minh, 700000, Vietnam

About this study

Upon arrival in the operating room, the parturient was monitored using standard American Society of Anesthesiologists monitors, including electrocardiography, pulse oximetry, and invasive arterial BP measurement. A large peripheral vein was cannulated using an 18-gauge intravenous catheter for the administration of fluids and medications. Baseline BP was determined by averaging three measurements taken 2 minutes apart in the supine position before SA. Low-dose SA was performed with 8 mg of bupivacaine (Marcain) combined with 20 mcg of fentanyl and 100 mcg of morphine (Opiphine). At injection, patients received 15 ml/kg of 0.9% saline IV and group-specific vasopressors:

  • P group: Continuous intravenous phenylephrine infusion was administered at 0.25 mcg/kg/min, prepared by diluting 500 mcg in 50 mL of 0.9% sodium chloride.
  • N group: Continuous intravenous norepinephrine infusion was administered at 0.05 mcg/kg/min, prepared by diluting 100 mcg in 50 mL of 0.9% sodium chloride.

Following SA, patients were placed in a 15° left lateral tilt and administered 4 mg of ondansetron and 4 mg of dexamethasone intravenously. The sensory block was assessed at 10 minutes; a block at or above the xiphoid was considered effective. After placental delivery, uterotonics were administered as prescribed by the obstetrician. Vasopressor infusion was stopped 5 minutes after delivery.

BP and heart rate (HR) were recorded every 2 minutes during the first 30 minutes after SA, then every 5 minutes until the end of surgery. Neonatal HR was monitored continuously, and Apgar scores were assessed at 1 and 5 minutes by a neonatologist.

Management of Hemodynamic Events and Bradycardia Hypotension was defined as systolic blood pressure (SBP) < 90 mmHg or a drop of more than 20% from baseline. Management involved increasing the vasopressor infusion rate by 20%, followed by administration of phenylephrine 50 mcg intravenously if the HR was ≥ 75 bpm, or ephedrine 6 mg IV if HR was < 75 bpm. The infusion rate was returned to baseline once SBP recovered to the target range (80-120% of baseline).

Severe hypotension (SBP < 60% of baseline) was treated using the same approach but with a higher dose of rescue vasopressors: phenylephrine 100 mcg IV or ephedrine 12 mg IV, depending on HR.

In cases of hypertension (SBP > 120% of baseline), the vasopressor infusion was reduced by 50%. If the SBP exceeded 130%, the infusion was temporarily stopped and reinitiated at 50% of the original dose once the SBP returned to the target range.

Bradycardia was defined as a HR of less than 60 bpm. Management of bradycardia was based on the patient's hemodynamic status. If bradycardia occurred without hypotension, the vasopressor infusion was temporarily discontinued, and if the HR recovered to ≥ 60 bpm, the infusion was resumed at 50% of the original dose. Persistent bradycardia (>3 minutes) was treated with atropine 0.5 mg IV, up to 3 doses. If bradycardia was associated with hypotension, ephedrine 6 mg IV was administered.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Parturients aged ≥18 years
  • Classified as American Society of Anesthesiologists physical status II
  • Term singleton pregnancies
  • Scheduled for elective CD under SA

Exclusion criteria

  • Refusal to participate.
  • Fetal anomalies or suspected fetal compromise
  • Preeclampsia or eclampsia
  • Conversion to general anesthesia or use of labor analgesia
  • Contraindication to SA
  • Preexisting cardiovascular or cerebrovascular disease; chronic hypertension
  • Baseline bradycardia
  • Current use of cardiovascular or antihypertensive medications
  • Body mass index more than 40 kg/m²
  • Body weight less than 50 kg or more than 100 kg

Treatment and study plan

norepinephrine

Drug

Continuous intravenous norepinephrine infusion was administered at 0.05 mcg/kg/min, prepared by diluting 100 mcg in 50 mL of 0.9% sodium chloride

Phenylephrine

Drug

Continuous intravenous phenylephrine infusion was administered at 0.25 mcg/kg/min, prepared by diluting 500 mcg in 50 mL of 0.9% sodium chloride

Primary outcomes

  1. Hypotension

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered.

    Hypotension was defined as systolic blood pressure (SBP) < 90 mmHg or a drop of more than 20% from baseline.

Secondary outcomes

  1. Bradycardia

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered.

    Bradycardia was defined as a HR of less than 60 beat per minute.

  2. Hypertension

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered

    Hypertension was defined as systolic blood pressure (SBP) > 120% of baseline.

  3. Severe hypotension

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered

    Severe hypotension was defined as systolic blood pressure (SBP) < 60% of baseline

  4. Requirement for rescue vasopressors (phenylephrine or ephedrine) and atropine

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered

    Requirement for rescue vasopressors (phenylephrine or ephedrine) and atropine during vasopressor administration

  5. Nausea and vomiting

    Time frame: From the completion of spinal injection until 5 minutes after the neonate is delivered

    Maternal intraoperative nausea or vomiting during vasopressor administration

  6. Neonatal Apgar Score

    Time frame: At 1 and 5 minutes after birth

    The Apgar score is a standardized clinical assessment tool used to evaluate the physical condition of newborns immediately after birth. The title "Apgar" stands for Appearance, Pulse, Grimace, Activity, and Respiration. In this study, the assessment is performed by a qualified neonatologist. Each of the five criteria is scored from 0 to 2, resulting in a total score ranging from 0 to 10.

    Minimum Value: 0. Maximum Value: 10

    Interpretation:

    Scores 0-3: Critically low; indicates the newborn requires immediate life-saving resuscitation.

    Scores 4-6: Fairly low; indicates the newborn may require some resuscitative measures or close monitoring.

    Scores 7-10: Normal; indicates the newborn is in good to excellent condition. Direction: Higher scores represent a better clinical outcome for the neonate.

Sponsors and collaborators

Lead sponsor

Tam Anh Research Institute

Other

Registry information

Official study title

Comparison of Continuous Norepinephrine and Phenylephrine Infusion for Preventing Hypotension During Low-Dose Spinal Anesthesia in Cesarean Delivery: A Randomized Controlled Trial

Acronym: NORPHE-CD

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 8, 2026
Registry last updated
Jan 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.